---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-004579"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T04:17:44.521726+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Geron expects Q4 RYTELO revenue ~$45-46M; FY 2024 opex ~$250-260M, cash ~$500M

## Summary
- Preliminary Q4 2024 U.S. RYTELO net revenue expected $45M-$46M, first full quarter of launch.
- FY 2024 operating expenses estimated ~$250M-$260M; cash, equivalents, and securities ~$500M as of Dec 31, 2024.
- Estimates are preliminary, unaudited, subject to change upon completion of financial close and audit.
- RYTELO (imetelstat) is Geron's approved telomerase inhibitor for lower-risk myelodysplastic syndromes.

## SEC filing metadata
- accession: 0000950170-25-004579
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000095017025004579/0000950170-25-004579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000095017025004579/gern-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-004579
- JSON: https://secwatch.observer/filing/0000950170-25-004579.json
- Plain text: https://secwatch.observer/filing/0000950170-25-004579.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.